Endo Pharmaceuticals Collaborates to Develop Pain Treatments and Discover Potential Cancer Treatments
News Feb 11, 2009
Endo Pharmaceuticals has announced that it has signed two research collaboration agreements to develop novel treatments for pain and to discover potential treatments for cancer.
The first collaboration, with Harvard University, is based upon a new pain-drug-delivery technique discovered by Clifford Woolf, M.D., Ph.D., Harvard Medical School's Richard J. Kitz Professor of Anaesthesia Research at Massachusetts General Hospital, and Bruce Bean, Ph.D., Harvard Medical School Professor of Neurobiology, that targets pain-sensing neurons without affecting motor neurons.
Under the terms of the agreement, Endo will receive exclusive world-wide rights to the technology and be responsible for development and commercialization of any drug candidates discovered under the agreement.
The second agreement, with Aurigene Discovery Technologies Ltd., is a three-year collaboration to discover novel drug candidates to treat cancer.
Aurigene will be responsible for all discovery and preclinical research activities, while Endo will be responsible for all clinical development and commercialization of drug candidates that advance into human testing. Endo will also provide research funding and milestone payments and receive worldwide rights to all intellectual property that results from this collaboration.
Ivan Gergel, M.D., Endo executive vice president of research and development, stated: "We are very excited to be pursuing promising new avenues of research in pain management as well as cancer treatment. We look forward to working with our colleagues at Harvard to explore the potential to block pain without affecting motor or other functions, and with the team at Aurigene to discover new oncology drug candidates."
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Chemists Develop Method to Synthesize Drugs From Renewable PrecursorsNews
Researchers have developed a new approach to the synthesis of benzofurans from cheap raw materials.READ MORE